Mp70-16 Sema3c Drives Cancer Growth and Treatment Resistance via Cognate Ligand-Independent Activation
Journal of Urology - Netherlands
doi 10.1016/j.juro.2018.02.2260
Full Text
Open PDFAbstract
Available in full text
Categories
Date
April 1, 2018
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)